CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Prazosin +1 moredrug
Likely dose
Prazosin 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02966340
NCT02966340Phase 2Completed
CompareCT.gov

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

University of Wisconsin, Madison·interventional·Posted Nov 17, 2016·Updated May 28, 2019

In Brief

A Phase 2 clinical trial evaluating Prazosin and Placebo for Alcoholism. Completed, enrolled 70 participants across 1 site.

Detailed Summary

Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 17, 2016
Enrollment StartNov 1, 2016
Primary CompletionMar 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.6 years ago

Interventions

Prazosindrug

2mg Prazosin

Placebodrug

Placebo